ATAGI statement on the intradermal use of Imojev Japanese encephalitis vaccine
About this resource
Publication date:
Publication type:
Statement
Language:
English
Australian Government Department of Health, Disability and Ageing
ATAGI statement on the intradermal use of Imojev Japanese encephalitis vaccine
ATAGI has reviewed the evidence on the intradermal (ID) administration of Japanese encephalitis (JE) vaccines and considered the potential use of Imojev as a dose-sparing mechanism, in the context of the risk of future outbreaks, expanded eligibility in risk areas, and ongoing supply considerations.